Last reviewed · How we verify

GSK1349572 (dolutegravir) — Competitive Intelligence Brief

GSK1349572 (dolutegravir) (GSK1349572 (dolutegravir)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Integrase strand transfer inhibitor (INSTI). Area: Infectious Disease.

phase 3 Integrase strand transfer inhibitor (INSTI) HIV integrase Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

GSK1349572 (dolutegravir) (GSK1349572 (dolutegravir)) — ViiV Healthcare. Dolutegravir inhibits HIV integrase, preventing the virus from inserting its genetic material into human DNA.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
GSK1349572 (dolutegravir) TARGET GSK1349572 (dolutegravir) ViiV Healthcare phase 3 Integrase strand transfer inhibitor (INSTI) HIV integrase
Atripla (r) Atripla (r) Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections marketed Antiretroviral combination (NNRTI + NRTI + NtRTI) HIV reverse transcriptase, HIV integrase
All licensed antiretroviral medications All licensed antiretroviral medications University of Minnesota marketed Antiretroviral agents (multiple classes: NRTIs, NNRTIs, PIs, INSTIs, entry inhibitors) Multiple (HIV reverse transcriptase, HIV protease, HIV integrase, CCR5, CXCR4, gp120/gp41)
Doravirine, Tenofovir, Lamivudine Doravirine, Tenofovir, Lamivudine Merck Sharp & Dohme LLC marketed Antiretroviral combination (NNRTI + NRTIs) HIV reverse transcriptase, HIV integrase
Dolutegravir/Lamivudine as a single pill Dolutegravir/Lamivudine as a single pill Fundacion SEIMC-GESIDA marketed Antiretroviral combination (INSTI + NRTI) HIV integrase; HIV reverse transcriptase
elvitegravir/cobicistat/emtricitabine/Tenofovir-Disoproxil elvitegravir/cobicistat/emtricitabine/Tenofovir-Disoproxil Fundacion Clinic per a la Recerca Biomédica marketed Antiretroviral combination (integrase inhibitor + pharmacokinetic booster + nucleoside/nucleotide reverse transcriptase inhibitors) HIV integrase, CYP3A4, HIV reverse transcriptase
Switch to DTG + 3TC Switch to DTG + 3TC Hospitales Universitarios Virgen del Rocío marketed Antiretroviral combination (INSTI + NRTI) HIV integrase; HIV reverse transcriptase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Integrase strand transfer inhibitor (INSTI) class)

  1. ViiV Healthcare · 12 drugs in this class
  2. National Institute of Allergy and Infectious Diseases (NIAID) · 5 drugs in this class
  3. Merck Sharp & Dohme LLC · 5 drugs in this class
  4. Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal · 1 drug in this class
  5. Germans Trias i Pujol Hospital · 1 drug in this class
  6. Groupe d'Etude sur le Risque d'Exposition des Soignants aux Agents Infectieux · 1 drug in this class
  7. ANRS, Emerging Infectious Diseases · 1 drug in this class
  8. Massachusetts General Hospital · 1 drug in this class
  9. University of Colorado, Denver · 1 drug in this class
  10. MU-JHU CARE · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). GSK1349572 (dolutegravir) — Competitive Intelligence Brief. https://druglandscape.com/ci/gsk1349572-dolutegravir. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: